Trial Profile
Therapeutic effect of Peg-IFN therapy combined with RBV and simeprevir (SMV) on patients with chronic hepatitis C - a multicenter study -
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 23 Apr 2014 New trial record